CD269 protein

CD269(BCMA)-muIg-Purified (with Antibiotics)

Cat. Num. AAA666883

• Reactivity: Human
• Applications: ELISA
• Purity: Purified (with Antibiotics)
• Synonyms: CD269; CD269(BCMA)-muIg-Purified (with Antibiotics); Human CD269(BCMA)-muIg Fusion Protein; CD269 protein

• Host: CHO cells
• Reactivity: Human
• Purity/Purification: Purified (with Antibiotics)
• Form/Format: 50 mM Sodium Phosphate pH 7.5, 100 mM Potassium Chloride, 150mM NaCl, 0.5% Gentamicin sulfate
• Concentration: 0.5 mg/ml (varies by lot)

• Applicable Applications for CD269 protein: ELISA (EIA)
• Molecular Structure: A soluble molecule consisting of the extracellular (54aa) domain of human BCMA fused to the murine IgG2a Fc (232 aa). Predicted monomeric weight: 33 kd.
• Transfectant Cell Line: CHO
• Performance: Five x 105 human Raji cells were washed and incubated 45 minutes on ice with 80 ul of BAFF-muCD8 at 3 ug/ml. Cells were washed twice and incubated with 2 degree anti-muCD8a/PE, after which they were washed three times, fixed and analyzed by FACS. Cells stained positive with a mean shift of 1.2 log10 fluorescent units when compared to a buffer control. This binding was 88% inhibited when recombinant BAFF was pre incubated with 50 ug/ml BCMA-muIg.
• Production: Human BCMA-muIg fusion protein was purified from (low FBS containing) tissue culture supernatant of CHO transfectants using Protein A and size exclusion chromatography. Product was 0.2u sterile filtered and vialed under aseptic conditions.
• Buffer: 50 mM Sodium Phosphate pH 7.5, 100 mM Potassium Chloride, 150mM NaCl, 0.5 mg/ml Gentamicin sulfate (as a preservative).
• Group Header: CD269(BCMA)-muIg
• Preparation and Storage: Store at 2 - 5 degree C. Freeze/Thawing is not recommended.; Product should retain activity for at least 6 months after shipping date when stored as recommended.

Testing Data

Related Product Information for CD269 protein

Information: The human B cell activating factor (BAFF) and APRIL(a proliferation inducing ligand) are both type II molecules belonging to the TNF superfamily. They are expressed by non-B cells, and are down regulated by mitogenic stimulation(2). BAFF and APRIL bind to at least two receptors: TACI (transmembrane activator and CAML-interactor) and BCMA (B cell maturation antigen), both of which are restricted to B cells(3,4). Ligation of these receptors with recombinant BAFF dramatically increases IgM production by peripheral blood B cells(1). Recently a third receptor for BAFF (BAFF-R) was described(5). BAFF and BAFFR knockout mice have a reduced numbers of mature B cells in the periphery, however TACI and BCMA knockouts do not share this phenotype, suggesting that BAFF-R may the primary receptor for BAFF in mice(8,9,10). Cell surface BAFF can be proteolytically cleaved to form a soluble trimeric molecule(2). Levels of soluble BAFF correspond with levels of autoantibodies in Sjogren's Syndrome(11). Recombinant human BCMA-muIg binds to recombinant BAFF-muCD8 and can inhibit binding of this molecule to receptors on Raji cells.

References

1) Schneider P., J. Tschopp, et al. J. Exp. Med. 1999, 189(11):1747-1756. 2) Shu, H.B., H. Johnson, W.H. Hui. J Leukoc Biol 1999, 65:680-683. 3) Marsters, S.A., A. Ashkenazi, et al. 2000, Curr Biol 10:785-788. 4) Xia, X., H. Hsu, et al. 2000, J Exp Med, 192(1): 137-143. 5) Thompson J.S., C. Ambrose, et al. Science 2001, 293: 2108-2111. 6)Roschke,V, T.S. Migone, et al. J Immunol. 2002, 169: 4314-4321. 7) MacLennan, C.M., C.G. Vinuesa, 2002, Immunity 17:235-238. 8) B. Schiemann, et al, (2001) Science 293: 2111-2114. 9) S.M. Harless,et al, (2001) Curr Biol 11: 1988-1989. 10) Mol Cell Biol (2001) 21: 4067-4074. 11) X. Mariette, et al, (2003) Ann Rhem Dis 62: 168-171